- Home
- EUDA vs INKT Comparison
EUDA vs INKT Comparison
Compare EUDA & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EUDA | INKT |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 57.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EUDA | INKT |
|---|---|---|
| Price | $1.55 | $12.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.3M | 11.8K |
| Earning Date | 12-19-2023 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $5,160,280.00 | N/A |
| Revenue This Year | $137.25 | N/A |
| Revenue Next Year | $361.43 | N/A |
| P/E Ratio | $225.42 | ★ N/A |
| Revenue Growth | ★ 83.73 | N/A |
| 52 Week Low | $1.03 | $4.56 |
| 52 Week High | $4.50 | $76.00 |
Technical Indicators
Market Signals| Indicator | EUDA | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 54.00 |
| Support Level | $2.26 | $11.28 |
| Resistance Level | $2.09 | $12.31 |
| Average True Range (ATR) | 0.34 | 0.49 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 7.43 | 78.31 |
Price Performance
Historical ComparisonAbout EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.